Anti-inflammatory approaches that target neutrophils, macrophages, and T cells [100,101,105], inhibition of cytokines such as IL-6, IL-17, and TNF-α [102,106,107], or modulate T-reg cells [103], have shown protective effects in experimental stroke, preventing GI barrier damage and permeability associated with BT. The gene discussed is IL17A; the disease is stroke disorder.